My main research focus is based on the development of population based approaches to genetic testing for risk stratification, cancer prevention and using targeted surgical approaches for cancer prevention in gynaecological cancers.
A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol (2019). PMID: 31580391
Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation-testing in unselected general-population women. J Natl Cancer Inst (2018); 110(7):714-725. PMID: 29361001
Cost effectiveness of population screening for BRCA mutations in Ashkenazi-Jewish women compared to family-history based testing. J Natl Cancer Inst (2015); 107(1):380. PMID: 25435542
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomised controlled trial. J Natl Cancer Inst (2015); 107(1):379. PMID: 25435541
Specifying the risk threshold of premenopausal risk reducing salpingo-oophorectomy for ovarian cancer prevention: a cost-effectiveness analysis. J Med Genet (2016); 53(9):591-9. PMID: 27354448
Cluster randomised non-inferiority trial comparing DVD-based and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. J Med Genet (2016); 53(7):472-80. PMID: 26993268
My research interests include:
Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS Taylor JA, Burnell M, Ryan A et al. BJOG: An International Journal of Obstetrics and Gynaecology (2022) 129(7) 110-118
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic. Taylor A, Sundar SS, Bowen R et al. Int J Gynecol Cancer (2022) 32(2) 9-14
Concise Reporting of Benign Endometrial Biopsies is an Acceptable Alternative to Descriptive Reporting. Kriplani D, Olivar AA, Tchrakian N et al. Int J Gynecol Pathol (2022) 41(2) 20-27
Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 Manchanda R, Gaba F, Talaulikar V et al. BJOG: An International Journal of Obstetrics and Gynaecology (2022) 129(7) e16-e34
Special Issue “Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer” Manchanda R Cancers (2022) 14(7)
Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study. Sundar S, Cummins C, Kumar S et al. BJOG (2021) (2)
Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. Lee A, Yang X, Tyrer J et al. J Med Genet (2021) (2)
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II Oonk MHM, Slomovitz B, Baldwin PJW et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021) 39(7) 3623-3632
423 Results of the avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance program for BRCA mutation-carriers Philpott S, Raikou M, Manchanda R et al. International Journal of Gynecological Cancer (2021) 31(10) a373-a374
COVID-19 and the impact on gynecologic cancer care Manchanda R, Oxley S, Ghaem-Maghami S et al. International Journal of Gynecology and Obstetrics (2021) (1)For additional publications, please click here
Senior Research Fellow
Clinical Trials Coordinator
Ms Dhivya Chandrasekaran, Ms Faiza Gaba
I joined Barts Cancer Institute as a Clinical Senior Lecturer and Consultant Gynaecological Oncologist in June 2015. I was awarded an NHS Innovation Accelerator Fellowship in March 2019.
I previously worked as a Consultant Gynaecological Oncologist at St Bartholomew’s Hospital (2014- 2015) & an Honorary Senior Lecturer at University College London, UK.
I completed a PhD in gynaecological oncology at UCL, along with a NIHR ACL Fellowship and subspecialty training in gynaecological oncology from UCLH and Bart's Hospital. I have served as the president of the European Network of young Gynaecological Oncologists (ENYGO) and a member of the European Society of Gynaecological Oncology (ESGO) council (2011-2013).
I am co-Lead for the Prevention Theme at the CRUK Barts Centre. I chair the Gynecological Oncology clinical trials group at Barts & Queen Mary University of London and am Co-PI of the BCI Gynae Tissue Bank. I am a member of the NCRI Ovarian Cancer Surgical Sub group. I am Acting-PI, research lead of the GCaPPS (Genetic Cancer Prediction through Population Screening) trial; CI on PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) trial, the PROMISE Pilot Study (Feasibility of population-based risk prediction and stratification for targeted ovarian cancer prevention), and the SIGNPOST (SystematIc GeNetic testing for Personalised Ovarian cancer Therapy) study. I am a co-investigator of the ‘Predicting Risk of Ovarian Malignancy, Improving Screening and Early detection’ (PROMISE) 2016 programme, member of the ALDO (Avoiding Late Diagnosis of Ovarian cancer) and UKFOCSS (UK Familial Ovarian Cancer Screening Study) teams. I lead the Bart's Hospital High risk Precision Medicine and Cancer Prevention Clinical service and Chair the London Cancer high-risk gynaecological cancer MDT. I am scientific advisor to BRCA Umbrella and Chair the Independent Advisory Committee of the Mermaid Project (Demark).
I am actively involved in gynaecological oncology training issues, have helped develop and establish ENYGO (European Network of Young Gynaecological Oncologists) from its inception and both led and undertaken a number of initiatives for European and International trainees in gynaecological oncology. I am the Integrated Academic Training Programme Director and lead for the RCOG Advanced Professional Module (APM) in Clinical Research for North Central and North East London, London Specialty School of Obstetrics & Gynaecology. I am the deputy director of the Barts Health RCOG gynaecological oncology training programme and Mentor for the IGCS Gynecologic Oncology Global Curriculum & Mentorship Program. I am a member of the International Gynecological Cancer Society (IGCS) Education Steering Committee, the British Gynecological Cancer Society (BGCS) International Subcommittee.
Education & Qualifications